Stock Analysis

Estrima Full Year 2023 Earnings: €2.37 loss per share (vs €0.61 loss in FY 2022)

BIT:BIRO
Source: Shutterstock

Estrima (BIT:BIRO) Full Year 2023 Results

Key Financial Results

  • Revenue: €44.2m (up 15% from FY 2022).
  • Net loss: €11.9m (loss widened by 285% from FY 2022).
  • €2.37 loss per share (further deteriorated from €0.61 loss in FY 2022).
revenue-and-expenses-breakdown
BIT:BIRO Revenue and Expenses Breakdown July 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Estrima Earnings Insights

The primary driver behind last 12 months revenue was the Italy segment contributing a total revenue of €26.9m (61% of total revenue). Notably, cost of sales worth €37.8m amounted to 86% of total revenue thereby underscoring the impact on earnings. The most substantial expense, totaling €8.11m were related to Non-Operating costs. This indicates that a significant portion of the company's costs is related to non-core activities. Explore how BIRO's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 2.9% p.a. on average during the next 3 years, compared to a 2.7% growth forecast for the Auto industry in Europe.

Performance of the market in Italy.

The company's shares are up 2.1% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 4 warning signs for Estrima (of which 2 are significant!) you should know about.

Valuation is complex, but we're helping make it simple.

Find out whether Estrima is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're helping make it simple.

Find out whether Estrima is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com